Zhejiang Dongsheng Pharmaceutical

Zhejiang Dongsheng Pharmaceutical is a prominent Chinese pharmaceutical manufacturer specializing in the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms. Established in 1993 and headquartered in Shaoxing, the company focuses on high-volume therapeutic areas, particularly metabolic health, cardiovascular diseases, and gastroenterology. Its commercial portfolio includes widely prescribed generic treatments such as Metformin and Gliclazide for type 2 diabetes, as well as Felodipine for hypertension. The company operates modern, GMP-certified facilities and is a key supplier within China's national volume-based procurement (VBP) framework, ensuring broad access to high-quality chronic disease medications. In addition to its domestic presence, Zhejiang Dongsheng exports products to various international markets, leveraging its expertise in small molecule chemical synthesis and advanced formulation development.